Update of cetuximab for non-melanoma skin cancer

Expert Opinion on Biological Therapy

Volumn 14, Issue 2, 2014, Pages 271-276

  Wollina, Uwe ^a  

^a ACADEMIC TEACHING HOSPITAL DRESDEN FRIEDRICHSTADT   (Germany)

Author keywords

Cetuximab; Epidermal growth factor receptor; Non melanoma skin cancer; Skin toxicity; Targeted therapy

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLUOROURACIL; IMATINIB; PACLITAXEL; VISMODEGIB;

ADVANCED CANCER; ARTICLE; BASAL CELL CARCINOMA; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RISK; DRUG EFFICACY; EPITHELIUM TUMOR; HIGH RISK PATIENT; HUMAN; MONOTHERAPY; NON MELANOMA SKIN CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SKIN CARCINOMA; SKIN TOXICITY; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIALS AS TOPIC; HUMANS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 84891920938     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2013.876406     Document Type: Article

References (40)

1. Dubas LE, Ingraffea A. Nonmelanoma skin cancer. Facial Plast Surg Clin North Am 2013;21:43-53
2. Etzkorn JR, Parikh RP, Marzban SS, et al. Identifying risk factors using a skin cancer screening program. Cancer Control 2013;20:248-54
3. Ettorre GM, Piselli P, Galatioto L, et al. De novo malignancies following liver transplantation: results from a multicentric study in central and southern Italy, 1990-2008. Transplant Proc 2013;45:2729-32
4. Muehleisen B, Pazhenkottil A, French LE, Hofbauer GF. Nonmelanoma skin cancer in organ transplant recipients: increase without delay after transplant and subsequent acceleration. JAMA Dermatol 2013;149:618-20
5. Wollina U. Addiction to tanning-a new cause of early onset of nonmelanoma skin cancer. Open Dermatol J 2009;3:86-8
6. Wu TP, Stein JA. Nonmelanoma skin cancer in young women. J Drugs Dermatol 2013;12:568-72
7. Cardoso JC, Teixeira V, Tchernev G, Wollina U. Merkel cell carcinoma: a review and update on aetiopathogenesis, diagnosis and treatment approaches. Wien Med Wochenschr 2013;163:359-67
8. Maibach HI, Gouruhi F. Evidence based dermatology. 2nd edition. Shelton/Co., People's Medical Publishing House, USA; 2011. p. 649-88
9. Wollina U, Tchernev G. Advanced basal cell carcinoma. Wien Med Wochenschr 2013;163:347-53
10. Desch L, Kunstfeld R. Merkel cell carcinoma: chemotherapy and emerging new therapeutic options. J Skin Cancer 2013;2013:327150
11. Yin VT, Pfeiffer ML, Esmaeli B. Targeted therapy for orbital and periocular basal cell carcinoma and squamous cell carcinoma. Ophthal Plast Reconstr Surg 2013;29:87-92
12. Wollina U. Cetuximab for non-melanoma skin cancer. Expert Opin Biol Ther 2012;12:949-56
13. Normanno N, De Luca A, Bianco C, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006;366:2-16
14. Karia PS, Han J, Schmults CD. Cutaneous squamous cell carcinoma: estimated incidence of disease, nodal metastasis, and deaths from disease in the United States, 2012. J Am Acad Dermatol 2013;68:957-66
15. Brougham ND, Dennett ER, Cameron R, Tan ST. The incidence of metastasis from cutaneous squamous cell carcinoma and the impact of its risk factors. J Surg Oncol 2012;106:811-15
16. O'Bryan K, Sherman W, Niedt GW, et al. An evolving paradigm for the workup and management of high-risk cutaneous squamous cell carcinoma. J Am Acad Dermatol 2013;69:595-602
17. Rahimi S. Squamous cell carcinoma of skin: a brief review. Clin Ter 2013;164:143-7
18. Eisenhauer E, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version1.1). Eur J Cancer 2009;45:228-47
19. Maubec E, Petrow P, Scheer-Senyarich I, et al. Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J Clin Oncol 2011;29:3419-26
20. Eder J, Simonitsch-Klupp I, Trautinger F. Treatment of unresectable squamous cell carcinoma of the skin with epidermal growth factor receptor antibodies-a case series. Eur J Dermatol 2013;23(5):658-62
21. Kalapurakal SJ, Malone J, Robbins KT, et al. Cetuximab in refractory skin cancer treatment. J Cancer 2012;3:257-61
22. Mecca C, Ponzetti A, Clainedo V, et al. Complete response of metastatic cutaneous squamous cell carcinoma to cetuximab plus paclitaxel. Eur J Dermatol 2012;22:758-61
23. Wollina U, Schreiber A, Merla K, Haroske G. Combined cetuximab and volumetric modulated arc-radiotherapy in advanced recurrent squamous cell carcinoma of the scalp. Dermatol Rep 2011;3:e57
24. Giacchero D, Barriere J, Benezery K, et al. Efficacy of cetuximab for unresectable or advanced cutaneous squamous cell carcinoma-a report of eight cases. Clin Oncol (R Coll Radiol) 2011;23:716-18
25. Carthon BC, Ng CS, Pettaway CA, Pagliaro LC. Epidermal growth factor receptor-targeted therapy in locally advanced or metastatic squamous cell carcinoma of the penis. BJU Int 2013, doi:10.1111/bju.12450
26. Kasper M, Jaks V, Hohl D, Toftgard R. Basal cell carcinoma-molecular biology and potential new therapies. J Clin Invest 2012;122:455-63
27. Brunner M, Thurnher D, Pammer J, et al. Expression of VEGF-A/C, VEGF-R2, PDGF-alpha/beta, c-kit, EGFR, Her-2/Neu, Mcl-1 and Bmi-1 in Merkel cell carcinoma. ModPathol 2008;21:876-84
28. Nardi V, Song Y, Santamaria-Barria JA, et al. Activation of PI3K signalling in Merkel cell carcinoma. Clin Cancer Res 2012;18:1277-36
29. Cardoso JC, Teixeira V, Tchernev G, Wollina U. Merkel cell carcinoma: a review and update on aetiopathogenesis, diagnosis and treatment approaches. Wien Med Wochenschr 2013;163:359-67
30. Grande R, Narducci F, Bianchetti S, et al. Pre-emptive skin toxicity treatment for anti-EGFR drugs: evaluation of efficacy o skin moisturizers and lymecycline. A phas II study. Support Care Cancer 2013;21:1691-5
31. Wehler TC, Graf C, Mohler M, et al. Cetuximab-induiced skin exanthema: prophylactic and reactive skin therapy are equally effective. J Cancer Res Clin Oncol 2013; 139:1667-72
32. Pinto C, Barone CA, Girolomoni G, et al. Management of skin toxicity associated with cetuximab treatment in combination with chemotherapy or radiotherapy. Oncologist 2011;16:228-38
33. Kajizono M, Saito M, Maeda M, et al. Cetuximab-induced skin reactions are suppressed by cigarette smoking in patients with advanced colorectal cancer. Int J Clin Oncol 2013;18:684-8
34. German Cancer Society (DKG). Skin cancer screening. Available from: www. hautkrebs-screening.de/aerzte/hautkrebs/haeufigkeit.php [Last accessed 1 November 2013]
35. Acevedo-Henao CM, Valette G, Miglierini P, et al. Radiotherapy combined with cetuximab for locally advanced head and neck cancer: results and toxicities. Cancer Radiother 2012;16:601-3
36. Okano S, Yoshino T, Fujii M, et al. Phase II study of cetuximab plus concomitant boost radiotherapy in Japanese patients with locally advanced squamous cell carcinoma of the head and neck. Jpn J Clin Oncol 2012;43:476-82
37. Knoedler M, Gauler TC, Gruenwald V, et al. Phase II study of cetuximab in combination with docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck after platinum-containing therapy: a multicenter study of the Arbeitsgemeinschaft Internistische Onkologie. Oncology 2013;84:284-9
38. Bossi P, Kornek G, Lanzetta G, et al. Safety and feasibility of every-other-week maintenance cetuximab after first-line chemotherapy in patients with recurrent or metastatic head and neck squamous cell cancer. Head Neck 2013;35:1471-4
39. Matuschek C, Bolke E, Belka C, et al. Feasibility of 6-month maintenance cetuximab after adjuvant concurrent chemoradiation plus cetuximab in squamous cell carcinoma of the head and neck. Strahlenther Onkol 2013;189:625-31
40. Strojan P, Kuhar CG, Zumer B, et al. TPF induction chemotherapy and concomitant irradiation with cisplatin and cetuximab in unresectable squamous cell carcinoma of the head and neck. Head Neck 2013, doi:10.1002/hed.23506